Do not miss any of the new cases! Subscribe above to receive our newsletter! ↑↑

Do not miss the opportunity to download our app on the Google Play Store. Click here to enjoy it.


Case 408


Click on the images above to zoom in

An 81-year-old woman who presented with a 15-day history of chest discomfort, onset over two hours with continuous, squeezing, retrosternal pain, not relieved by rest and without radiation. Past medical history: coronary artery disease (CAD), arterial hypertension, dyslipidemia and ischemic stroke in 2010. On examination, HR: 120 bpm, electrocardiography (image 1) and troponin I: 0,057ng/mL (RV: 0,034ng/mL). No other comorbidities related.

According to the clinical history and the electrocardiographic findings presented, what is the probable diagnosis? Abbreviations: STEMI - ST-segment elevation myocardial infarction; NSTEMI - non-ST elevation myocardial infarction

a) Type 2 MI, NSTEMI, caused by atrial fibrillation due to rapid ventricular response.


b) Type 1 MI, STEMI, precipitated by atherosclerotic plaque disruption.


c) Type 2 MI, NSTEMI, caused by sinus tachycardia.


d) Unstable angina, there is not enough evidence to diagnose myocardial infarction.


Image analysis

Image 1 - Electrocardiography, I, II and III leads presenting irregular rhythm  (irregular iRR - yellow arrows), P wave absence (blue circles), regular QRS complex length (


  • - One third of all deaths worldwide is caused by cardiovascular diseases, only acute coronary syndrome is responsible for 1,8 million deaths per year.

  • - MI diagnosis is made by anginal pain, electrocardiographic findings due to myocardial injury biomarkers.

  • - It is necessary to make the different diagnoses between MI type 1 and 2 for tepheutics purposes. 

  • - Acute atherothrombotic coronary artery disease, precipitated by atherosclerotic plaque disruption is the main cause of type 1 MI. On the other hand, type 2 MI is multifactorial, consequent to a mismatch between oxygen supply and demand.

  • - Fibrinolysis is not indicated in patients with type 2 MI and the primary cause resolution is essential for hemodynamic stabilization.


  • 1. Neumann J, Sörensen N, Rübsamen N, Ojeda F, Renné T, Qaderi V et al. Discrimination of patients with type 2 myocardial infarction. European Heart Journal. 2017;38(47):3514-3520. 

  • 2. Sanchis-Gomar F, Perez-Quilis C, Leischik R, Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Annals of Translational Medicine. 2016;4(13):256-256. 

  • 3. Thygesen K, Alpert J, Jaffe A, Chaitman B, Bax J, Morrow D et al. Fourth universal definition of myocardial infarction (2018). European Heart Journal. 2018;40(3):237-269. 


Ana Clara de Paula Caldas, 4th year medical student.

E-mail: anacpcaldas [at] 


Dr. Bruno Ramos Nascimento, cardiologist and professor of Minas Gerais Federal University (UFMG).

E-mail: ppchristo [at]


Marco Fontana; André Luís Drumond; Flávio Augusto Paes; Melina Araújo, Renata Aguiar, prof. Júlio Guerra Domingues.

Translated by:

Ana Clara de Paula Caldas, 3rd year medical student.

E-mail: anacpcaldas [at]

Test question

Residência Médica 2015 (ACESSO DIRETO 1) - Sistema único de saúde - SUS - São Paulo SP

In patients with acute coronary syndrome who have increased troponin and CK-MB, presenting NSTEMI, there is no evidence of benefit in the use of:


a) EV nitroglycerin


b) Low molecular weight heparin


c) Conventional heparin


d) Antiplatlet agents


e) Thrombolytics



Sorry, there is a database connection problem.

Please check back again shortly.

Bookmark and Share

Unfortunately there is no english translation available yet for this case.

Please refer to the Portuguese version instead or come back later.

Follow us:      Twitter  |    Facebook  |    Get the news  |    E-mail